Shaanxi Micot Reports Positive Phase II Stroke Trial Results
The company said MT200605’s high-dose arm met the primary endpoint and key secondary endpoints in a Phase II acute ischemic stroke trial, with favorable safety. It signaled plans for Phase III trials and potential partnerships outside China.